Patient-Derived Microvesicles/AIE Luminogen Hybrid System for Personalized Sonodynamic Cancer Therapy in Patient-Derived Xenograft Models
2020
Sonodynamic therapy (SDT), as an efficient
way of tumor treatment, has the advantages of deep tumor penetration and high therapeutic
efficacy. However, developing efficient sonosensitizers are still challenging. AIEgen-based SDT has never been reported and it is
urgent to develop novel AIEgen-active sonosensitizers. Furthermore, the AIEgen-based
theranostic system is promisingly needed to be proved on PDX models to be
closer to the clinic. Herein, we constructed the first AIEgen based SDT system
and found that DCPy has advantages over traditional sonosensitizers in SDT. Then, a patient-derived
MVs/AIEgen hybrid system prepared by electroporation was used for personalized
SDT in bladder cancer patient-derived xenograft (PDX) models. Impressively,
AMVs displayed the superior tumor targeting ability and efficient personalized
SDT therapy on PDX models, both of which were much more improved compared with
PLGA/AIEgens nanoparticles and cell line-derived micro vesicles. This work presented
the first example of an AIEgen-based hybrid system as sonosensitizer
for SDT and provides new ideas for both the design of AIE-active sonosensitizers
and the SDT treatment of cancers, further expanding the potential clinical
application of AIEgens in the future.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI